



CIN : L51109PB2002PLC047444

Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 13.08.2019

To,
Department of Corporate Services,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai - 400 001.

To,
Listing Department,
**Metropolitan Stock Exchange of India
Ltd. (MSE)**
Vibgyor Towers, 4th floor,
Plot No C 62, G - Block,
Opp. Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 098, India.

ISIN : INE730E01016
SYMBOL: PRISMEDI

Scip Code: 512217

Subject: Outcome of Board Meeting held on Tuesday, 13th August, 2019

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on **Tuesday, 13th August 2019 at 3:00 p.m. and concluded at 4:15 p.m.:**

1. Considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2019.
2. Considered and approved the appointment of M/s P. Chadha & Associates as a new Secretarial Auditor of the Company for the Financial Year ended 31st March, 2019.

You are requested to take the same on record and acknowledge receipt.

Thanking You,

For **PRISM MEDICO & PHARMACY LIMITED**

(Swati Pandey)
Company Secretary
M.No. A54947



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th June 2019 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date : 13-08-2019
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N

CA Harjeet Singh
Partner
M. No 095466



PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444


STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH JUNE, 2019

STANDALONE STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	30.06.2019	31.03.2019
I.EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	606.34	606.34
(B) RESERVES AND SURPLUS	728.97	708.74
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	0.00	0.00
SUB-TOTAL - SHAREHOLDERS' FUNDS	1335.31	1315.09
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT	0.00	0.00
(3) MINORITY INTEREST *	0.00	0.00
(4) NON CURRENT LIABILITIES	0.00	0.00
(A) LONG TERM BORROWINGS	0.00	0.00
(B) DEFERRED TAX LIABILITIES (NET)	0.42	0.42
(C) OTHER NON-CURRENT LIABILITIES	0.00	0.00
(D) LONG-TERM PROVISIONS	0.00	0.00
SUB-TOTAL - NON-CURRENT LIABILITIES	0.42	0.42
(5) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS		0.00
(B) TRADE PAYABLE	527.63	356.81
(C) OTHER CURRENT LIABILITIES	11.65	19.26
(D) SHORT TERM PROVISIONS	9.03	5.64
SUB-TOTAL - CURRENT LIABILITIES	548.31	381.71
TOTAL EQUITY & LIABILITIES	1884.04	1697.22
II.ASSETS		
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	8.09	8.54
(B) GOODWILL ON CONSOLIDATION *	0.00	0.00
(C) NON CURRENT INVESTMENTS	1000.00	1000.00
(D) DEFERRED TAX ASSETS (NET)	0.42	0.00
(E) LONG TERM LOANS & ADVANCES	0.00	0.00
(F) OTHER NON CURRENT ASSETS	0.00	0.00
SUB-TOTAL - NON-CURRENT ASSETS	1008.51	1008.54
(2) CURRENT ASSETS		
(A) CURRENT INVESTMENTS	0.00	0.00
(B) INVENTORIES	99.32	96.16
(C) TRADE RECEIVABLES	680.91	375.83
(D) CASH AND CASH EQUIVALENTS	11.78	11.76
(E) SHORT TERM LOANS AND ADVANCES	70.10	197.12
(F) OTHER CURRENT ASSETS	13.42	7.83
SUB-TOTAL - CURRENT ASSETS	875.53	688.69
TOTAL-ASSETS	1884.04	1697.22

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Place : Mohali
Date : 13.08.2019

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.
For Prism Medico & Pharmacy Ltd.


Gursimran Singh
Director
DIN: 02209675

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLCO47444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Period Ended (UnAudited)	Year Ended (Audited)
	30.06.2019	31.03.2019	30.06.2018	30.06.2019	31.03.2019
INCOME FROM OPERATIONS					
A Net Sales/ Income From Operations	601.16	1018.71	571.42	601.16	3630.62
B Other Operating Income	0.00	21.87	0.00	0.00	21.87
Total Income from Operations	601.16	1040.58	571.42	601.16	3652.49
Other Income	0.00	0.00	0.00	0.00	0.00
TOTAL INCOME FROM OPERATIONS(1+2)	601.16	1040.58	571.42	601.16	3652.49
EXPENSES:					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchase of Stock-In-Trade	576.65	889.09	456.35	576.65	3528.17
Change In Inventories	-3.17	159.76	85.59	-3.17	-7.61
Employee Benefit Expenses	3.75	8.15	3.39	3.75	24.63
Finance Cost	0.00	0.00	0.00	0.00	0.02
Payment to BSE		0.87	3.05		5.72
Depreciation	0.44	0.67	0.67	0.44	2.67
Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately)	5.88	28.63	0.87	5.88	69.55
TOTAL EXPENSES	583.56	1087.17	549.92	583.56	3623.16
PROFIT / (LOSS) BEFORE TAX (3-4)	17.61	-46.59	21.50	17.61	29.33
TAX EXPENSE:					
(1) Current Tax	3.39	5.64	0.00	3.39	5.64
(2) Deferred Tax	0.42	-6.32	0.00	0.42	-6.32
(3) MAT Credit	5.58	6.94	0.00	5.58	6.94
NET PROFIT / (LOSS) FOR THE PERIOD	20.22	-38.96	21.50	20.22	36.95
Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00
Minority Interest *	0.00	0.00	0.00	0.00	0.00
NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (7+8+9) *	20.22	-38.96	21.50	20.22	36.95
Paid -up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34

For Prism Medico & Pharmacy Ltd.

Director
T. J. Srinivasan

12	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	708.74	671.80	718.81	708.74	671.80
13	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	-0.64	0.35	0.33	0.61
	(2)DILUTED	0.33	-0.64	0.35	0.33	0.61
14	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	-0.64	0.35	0.33	0.61
	(2)DILUTED	0.33	-0.64	0.35	0.33	0.61
	* Applicable in the case of consolidated results.					

Notes:


1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on August 13, 2019 after being reviewed by the Audit Committee.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
4. The figures for the quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year and the unaudited year to date figures for 9 months ended December 31, 2018, being the date of the end of the third quarter of the financial year, which were subjected to limited review.

**FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.**

For Prism Medico & Pharmacy Ltd.

Place : Mohali

Date: 13.08.2019


Gursimran Singh

Director

Director

DIN: 02209675



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report on Consolidated Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Consolidated Un-Audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th June 2019 ("the Statement") and its subsidiary naming M/s Healthy Biosciences Private Limited attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Consolidated Statement includes the financial results of the following entity naming M/s Healthy Biosciences Private Limited.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Consolidated Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date : 13-08-2019
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437

CA Harjeet Singh
Partner
M.No 095466



PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH JUNE, 2019

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	30.06.2019	31.03.2019
I.EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	606.00	606.34
(B) RESERVES AND SURPLUS	695.00	684.86
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	-	-
SUB-TOTAL - SHAREHOLDERS' FUNDS	1301.00	1291.20
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT	-	-
(3) MINORITY INTEREST *	-	-
(4) NON CURRENT LIABILITIES	-	-
(A) LONG TERM BORROWINGS	0.00	0.00
(B) DEFERRED TAX LIABILITIES (NET)	0.00	0.00
(C) OTHER NON-CURRENT LIABILITIES	0.00	2.63
(D) LONG-TERM PROVISIONS	-	-
SUB-TOTAL - NON-CURRENT LIABILITIES	0.00	2.63
(5) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS	138.00	226.98
(B) TRADE PAYABLE	890.00	574.47
(C) OTHER CURRENT LIABILITIES	13.00	19.48
(D) SHORT TERM PROVISIONS	9.00	5.64
SUB-TOTAL - CURRENT LIABILITIES	1050.00	826.57
TOTAL EQUITY & LIABILITIES	2351.00	2120.40
II.ASSETS		
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	892.00	891.47
(B) GOODWILL ON CONSOLIDATION*		0.00
(C) NON CURRENT INVESTMENTS	136.00	135.72
(D) DEFERRED TAX ASSETS (NET)	7.00	7.11
(E) LONG TERM LOANS & ADVANCES	0.00	0.00
(F) OTHER NON CURRENT ASSETS	0.00	2.30
SUB-TOTAL - NON-CURRENT ASSETS	1035.00	1036.60
(2) CURRENT ASSETS		
(A) CURRENT INVESTMENTS	0.00	0.00
(B) INVENTORIES	142.00	138.81
(C) TRADE RECEIVABLES	757.00	312.83
(D) CASH AND CASH EQUIVALENTS	37.00	40.69
(E) SHORT TERM LOANS AND ADVANCES	367.00	583.09
(F) OTHER CURRENT ASSETS	13.00	8.38
SUB-TOTAL - CURRENT ASSETS	1316.00	1083.80
TOTAL-ASSETS	2351.00	2120.40

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Place : Mohali

Date : 13.08.2019

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.

For Prism Medico & Pharmacy

Gursimran Singh

Director

Director

DIN: 02200675

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Period Ended (Unaudited)	Year Ended (Audited)
	30.06.2019	31.03.2019	30.06.2018	30.06.2019	31.03.2019
INCOME FROM OPERATIONS					
A Net Sales/ Income From Operations	868.00	1654.44	576.72	868.00	5442.80
B Other Operating Income	3.00	26.28	0.90	3.00	29.61
Total Income from Operations	871.00	1680.72	577.62	871.00	5472.41
Other Income	0.00	5.45	5.45	0.00	0.00
TOTAL INCOME FROM OPERATIONS (1+2)	871.00	1686.17	583.07	871.00	5472.41
EXPENSES:					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchase of Stock-In-Trade	841.00	1526.22	441.90	841.00	5313.08
Change In Inventories	-3.00	167.54	85.59	-3.00	10.29
Employee Benefit Expenses	3.75	10.61	3.39	6.00	27.09
Finance Cost		4.02	0.94		10.73
Payment to BSE		0.87	3.05		5.72
Depreciation	9.00	15.34	9.47	9.00	38.27
Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately)	12.25	34.70	1.36	10.00	76.89
TOTAL EXPENSES	863.00	1759.30	545.70	863.00	5482.07
PROFIT / (LOSS) BEFORE TAX (3-4)	8.00	-73.13	37.37	8.00	-9.66
TAX EXPENSE:					
(a) Current Tax	2.00	0.00	0.00	2.00	5.64
(b) Deferred Tax	0.00	0.00	0.00	0.00	-12.38
(c) MAT Credit	7.00	0.00	0.00	7.00	6.94
NET PROFIT / (LOSS) FOR THE PERIOD	13.00	-73.13	37.37	13.00	4.02
Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00
Minority Interest *	0.00	0.00	0.00	0.00	0.00

For Prism Medico & Pharmacy Ltd.

[Signature]
Director

NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (7+8+9) *	13.00	-73.13	37.37	13.00	4.02
Paid -up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	680.84	680.84		680.84	680.84
Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
(1)BASIC	0.21	-1.21	0.62	0.21	0.07
(2)DILUTED	0.21	-1.21	0.62	0.21	0.07
Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
(1)BASIC	0.21	-1.21	0.62	0.21	0.07
(2)DILUTED	0.21	-1.21	0.62	0.21	0.07
* Applicable in the case of consolidated results.					
Notes:					
1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on August 13, 2019 after being reviewed by the Audit Committee.					
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.					
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.					
4. The figures for the quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year and the unaudited year to date figures for 9 months ended December 31, 2018, being the date of the end of the third quarter of the financial year, which were not subjected to limited review.					
FOR & ON BEHALF OF THE BOARD PRISM MEDICO AND PHARMACY LTD. <i>For Prism Medico & Pharmacy Ltd.</i> Gursimran Singh Director					
Place : Mohali					
Date : 13/08/2019					